Citigroup
BOLT icon

Citigroup’s Bolt Biotherapeutics BOLT Stock Holding History

Citigroup’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158 Buy
+41
New +$193 ﹤0.01% 5503
2026
Q1 		– Sell
-256
Closed -$1.4K – 5966
2025
Q4 		$1.4K Buy
+256
New +$1.37K ﹤0.01% 5503
2024
Q1 		– Sell
-115
Closed -$2.58K – 5646
2023
Q4 		$2.58K Buy
+115
New +$2.24K ﹤0.01% 5401
2023
Q1 		– Sell
-2
Closed -$56 – 5517
2022
Q4 		$56 Sell
2
-23
-92% -$630 ﹤0.01% 5662
2022
Q3 		$1K Sell
25
-18
-42% -$745 ﹤0.01% 5606
2022
Q2 		$2K Sell
43
-368
-90% -$14.3K ﹤0.01% 5857
2022
Q1 		$22K Buy
411
+49
+14% +$3.3K ﹤0.01% 5094
2021
Q4 		$35K Buy
362
+220
+155% +$41.8K ﹤0.01% 5221
2021
Q3 		$36K Buy
142
+103
+264% +$29.1K ﹤0.01% 4913
2021
Q2 		$12K Sell
39
-3
-7% -$1.22K ﹤0.01% 5562
2021
Q1 		$28K Buy
+42
New +$27.3K ﹤0.01% 5045

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's BOLT Position: Q2 2026 in Review

Citigroup opened a new position in Bolt Biotherapeutics (BOLT) in Q2 2026: 41 shares worth $158. The stake represents ﹤0.01% of the portfolio and ranks #5503 among its holdings. This is a return to the name: Citigroup previously reported a position in BOLT as recently as Q4 2025.

Citigroup first reported a position in BOLT in Q1 2021 and has held it in 11 quarters since. The position peaked at $36K in Q3 2021. 23 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • Citigroup held 41 shares of Bolt Biotherapeutics worth $158 as of Q2 2026.
  • Bolt Biotherapeutics was a new Citigroup position in Q2 2026.
  • Bolt Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5503 holding.
  • Citigroup first reported a position in Bolt Biotherapeutics in Q1 2021 and has held it in 11 quarters since.
  • Citigroup's Bolt Biotherapeutics position peaked at $36K in Q3 2021.
  • 23 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.